Pharmacy-Based Medical Record Linkage Systems

Pharmacoepidemiology, Fifth Edition

Volumn , Issue , 2012, Pages 270-286

  Herings, Ron M C ^a,b   Pedersen, Lars ^c  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

AUPD; Birth defect; Cancer registration; Hospitalization; Laboratory test; Observational database; OPED; Pharmacoepidemiology; PHARMO; Record linkage

Indexed keywords

EID: 84881182423     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119959946.ch18     Document Type: Chapter

References (65)

1. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997; 44: 445-8.
2. Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) -new opportunities for research in pharmacoepidemiology in Norway. Norsk Epidemiologi 2008; 18: 129-36.
3. Klaukka T. The Finnish database on drug utilisation. Norwegian J Epidemiol 2001; 11: 19-22.
4. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register -opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16: 726-35.
5. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2010; 106: 86-94.
6. Morris AD, Boyle DI, MacAlpine R, Emslie-Smith A, Jung RT, Newton RW, et al. The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. BMJ 1997; 315: 524-8.
7. Herings RMC. PHARMO: A Record Linkage System for Postmarketing Surveillance of Prescription Drugs in the Netherlands [Doctorate]. Utrecht: Utrecht University, 1993.
8. Klinisk Epidemiologisk Afdeling. www.kea.au.dk/ (accessed June 2011).
9. PHARMO. www.pharmo.com (accessed June 2011).
10. Hallas J. Conducting pharmacoepidemiologic research in Denmark. Pharmacoepidemiol Drug Saf 2001; 10: 619-23.
11. Ehrenstein V, Antonsen S, Pedersen L. Existing data sources for clinical epidemiology: Aarhus University Prescription Database. Clin Epidemiol 2010; 2: 273-9.
12. Wagner G, Newcombe HB. Record linkage. Its methodology and application in medical data processing. Methods Inf Med 1970; 9: 121-38.
13. DuVall SL, Kerber RA, Thomas A. Extending the Fellegi-Sunter probabilistic record linkage method for approximate field comparators. J Biomed Inform 2010; 43: 24-30.
14. Herzog TN, Scheuren F, Winkler WE. Data Quality and Record Linkage Techniques. New York: Springer, 2007, p. 227.
15. Strom B, Kimmel S. Textbook of Pharmacoepidemiology, 4th edn. West Sussex, England: John Wiley and Sons, 2006.
16. Mason CA, Tu S. Data linkage using probabilistic decision rules: a primer. Birth Defects Res A Clin Mol Teratol 2008; 82: 812-21.
17. Goehring R. Identification of patients in medical data bases-soundex codes versus match code. Med Inform (Lond) 1985; 10: 27-34.
18. Baldwin JA. The Oxford Record Linkage Study as a medical information system. Proc R Soc Med 1972; 65: 237-9.
19. Tromp M, Ravelli AC, Meray N, Reitsma JB, Bonsel GJ. An efficient validation method of probabilistic record linkage including readmissions and twins. Methods Inf Med 2008; 47: 356-63.
20. Tromp M, Ravelli AC, Bonsel GJ, Hasman A, Reitsma JB. Results from simulated data sets: probabilistic record linkage outperforms deterministic record linkage. J Clin Epidemiol 2010; 64: 565-72.
21. van Herk-Sukel MP, van de Poll-Franse LV, Lemmens VE, Vreugdenhil G, Pruijt JF, Coebergh JW, et al. New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer 2010; 46: 395-404.
22. Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH, et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 2007; 29: 19-24.
23. van Herk-Sukel MP, van de Poll-Franse LV, Voogd AC, Nieuwenhuijzen GA, Coebergh JW, Herings RM. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population -based analysis. Breast Cancer Res Treat 2010; 122: 843-51.
24. Sorensen HT, Christensen T, Kjeldahl Schlosser H, Pedersen L. Use of Medical Databases in Clinical Epidemiology. Aarhus University, Denmark, 2008.
25. Eussen SR, de Jong N, Rompelberg CJ, Garssen J, Verschuren WM, Klungel OH. Effects of the use of phytosterol/-stanol-enriched margarines on adherence to statin therapy. Pharmacoepidemiol Drug Saf 2010; 19: 1225-32.
26. Penning-van Beest FJ, van den Haak P, Klok RM, Prevoo YF, van der Peet DL, Herings RM. Quality of life in relation to constipation among opioid users. J Med Econ 2010; 13: 129-35.
27. Peters BJ, Rodin AS, Klungel OH, Stricker BH, de Boer A, Maitland-van der Zee AH. Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction. Pharmacogenet Genomics 2010; 20: 766-74.
28. Peters BJ, Rodin AS, Klungel OH, van Duijn CM, Stricker BH, van't Slot R, et al. Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. Pharmacogenomics 2010; 11: 1065-76.
29. Herings RMC. Medicatiebewaking gebaat bij samenwerking. Pharm Weekblad 1997; 132: 1030-3.
30. Penning-van Beest FJA, van der Bij S, Erkens JA, Kessabi S, Groot M, Herings RM. Effect on non -persistent use of oral glucose -lowering drugs on HbA1c goal attainment. Curr Med Res Opin 2008; 24: 2523-9.
31. Penning-van Beest FJ, Termorshuizen F, Goettsch WG, Klungel OH, Kastelein JJ, Herings RM. Adherence to evidence -based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2006; 28: 154-9.
32. Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 2006; 28: 236-42.
33. Breekveldt-Postma NS, Herings RM. Persistence with antihypertensives related to formulation: the case of nifedipine. Ann Pharmacother 2005; 39: 237-42.
34. Hansen DG, Vach W, Rosholm JU, Sondergaard J, Gram LF, Kragstrup J. Early discontinuation of antidepressants in general practice: association with patient and prescriber characteristics. Fam Pract 2004; 21: 623-9.
35. Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf 2003; 12: 423-4.
36. Larsen J, Andersen M, Kragstrup J, Gram LF. High persistence of statin use in a Danish population: compliance study 1993 -1998. Br J Clin Pharmacol 2002; 53: 375-8.
37. Larsen J, Vaccheri A, Andersen M, Montanaro N, Bergman U. Lack of adherence to lipid -lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. Br J Clin Pharmacol 2000; 49: 463-71.
38. Stricker BH, Herings RM. Pleidooi voor het behoud van de Landelijke Medische Registratie voor betrouwbare informatie over de volksgezondheid en de gezondheidszorg. Ned Tijdschr Geneeskd 2006; 150: 1916-7.
39. Heintjes EM, Hirsch MW, Van der Linden MW, O'Donnell JC, Stalenhoef AF, Herings RMC. LDL-C reductions and goal attainment among naive statin users in the Netherlands: real life results. Curr Med Res Opin 2008; 24: 2241-50.
40. Erichsen R, Froslev T, Lash TL, Pedersen L, Sorensen HT. Long-term statin use and the risk of gallstone disease: A population -based case -control study. Am J Epidemiol 2011; 173: 162-70.
41. Heintjes EM, Thomsen TL, Penning-van Beest FJ, Christensen TE, Herings RM. Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes. Adv Ther 2010; 27: 211-22.
42. Kornum JB, Thomsen RW, Riis A, Lervang HH, Schonheyder HC, Sorensen HT. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population -based case -control study. Diabetes Care 2008; 31: 1541-5.
43. Kanstrup H, Lassen JF, Heickendorff L, Lauritzen T, Larsen ML. Quality of lipid -lowering therapy in patients with ischaemic heart disease: a register -based study in 3477 patients. J Intern Med 2004; 255: 367-72.
44. Larsen J, Andersen M, Bjerrum L, Kragstrup J, Gram LF. Insufficient use of lipid -lowering drugs and measurement of serum cholesterol among patients with a history of myocardial infarction. J Cardiovasc Risk 2003; 10: 61-4.
45. PALGA. The nationwide network and registry of histo - and cytopathology in the Netherlands. www.palga.nl (accessed June 2011).
46. Koomen ER, Joosse A, Herings RM, Casparie MK, Guchelaar HJ, Nijsten T. Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population -based case -control study. Ann Oncol 2009; 20: 358-64.
47. Koomen ER, Joosse A, Herings RM, Casparie MK, Bergman W, Nijsten T, et al. Is statin use associated with a reduced incidence, a reduced Breslow thick ness or delayed metastasis of melanoma of the skin? Eur J Cancer 2007; 43: 2580-9.
48. Joosse A, Koomen ER, Casparie MK, Herings RM, Guchelaar HJ, Nijsten T. Non-steroidal anti -inflammatory drugs and melanoma risk: large Dutch population-based case -control study. J Invest Dermatol 2009; 129: 2620-7.
49. Dezentje VO, van Blijderveen NJ, Gelderblom H, Putter H, van Herk-Sukel MP, Casparie MK, et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 2010; 28: 2423-9.
50. Jensen AO, Thomsen HF, Engebjerg MC, Olesen AB, Friis S, Karagas MR, et al. Use of oral glucocorticoids and risk of skin cancer and non -Hodgkin's lymphoma: a population -based case -control study. Br J Cancer 2009; 100: 200-5.
51. Sukel MP, Breekveldt-Postma NS, Erkens JA, van der Linden PD, Beiderbeck AB, Coebergh JW, et al. Incidence of cardiovascular events in breast cancer patients receiving chemotherapy in clinical practice. Pharmacoepidemiol Drug Saf 2008; 17: 125-34.
52. Ewertz M, Mellemkjaer L, Poulsen AH, Friis S, Sorensen HT, Pedersen L, et al. Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer 2005; 92: 1293-7.
53. Goettsch WG, Sukel MP, van der Peet DL, van Riemsdijk MM, Herings RM. In-hospital use of opioids increases rate of coded postoperative paralytic ileus. Pharmacoepidemiol Drug Saf 2007; 16: 668-74.
54. Sturkenboom MC, Goettsch WG, Picelli G, in 't Veld B, Yin DD, de Jong RB, et al. Inappropriate initial treatment of secondary intra -abdominal infections leads to increased risk of clinical failure and costs. Br J Clin Pharmacol 2005; 60: 438-43.
55. Ratanajamit C, Vinther Skriver M, Jepsen P, Chongsuvivatwong V, Olsen J, Sorensen HT. Adverse pregnancy outcome in women exposed to acyclovir during pregnancy: a population -based observational study. Scand J Infect Dis 2003; 35: 255-9.
56. Olesen C, Sondergaard C, Thrane N, Nielsen GL, de Jong-van den Berg L, Olsen J. Do pregnant women report use of dispensed medications? Epidemiology 2001; 12: 497-501.
57. Olesen C, Thrane N, Nielsen GL, Sorensen HT, Olsen J. A population -based prescription study of asthma drugs during pregnancy: changing the intensity of asthma therapy and perinatal outcomes. Respiration 2001; 68: 256-61.
58. Fonager K, Larsen H, Pedersen L, Sorensen HT. Birth outcomes in women exposed to anticonvulsant drugs. Acta Neurol Scand 2000; 101: 289-94.
59. Sorensen HT, Johnsen SP, Larsen H, Pedersen L, Nielsen GL, Moller M. Birth outcomes in pregnant women treated with low -molecular -weight heparin. Acta Obstet Gynecol Scand 2000; 79: 655-9.
60. Larsen H, Nielsen GL, Sorensen HT, Moller M, Olsen J, Schonheyder HC. A follow -up study of birth outcome in users of pivampicillin during pregnancy. Acta Obstet Gynecol Scand 2000; 79: 379-83.
61. Olesen C, Steffensen FH, Sorensen HT, Nielsen GL, Olsen J. Pregnancy outcome following prescription for sumatriptan. Headache 2000; 40: 20-4.
62. Sorensen HT, Nielsen GL, Christensen K, Tage-Jensen U, Ekbom A, Baron J. Birth outcome following maternal use of metoclopramide. The Euromap study group. Br J Clin Pharmacol 2000; 49: 264-8.
63. Nielsen GL, Sorensen HT, Thulstrup AM, Tage-Jensen U, Olesen C, Ekbom A. The safety of proton pump inhibitors in pregnancy. Aliment Pharmacol Ther 1999; 13: 1085-9.
64. Sorensen HT, Nielsen GL, Olesen C, Larsen H, Steffensen FH, Schonheyder HC, et al. Risk of malformations and other outcomes in children exposed to fluconazole in utero. Br J Clin Pharmacol 1999; 48: 234-8.
65. Olesen C, Steffensen FH, Nielsen GL, de Jong-van den Berg L, Olsen J, Sorensen HT. Drug use in first pregnancy and lactation: a population -based survey among Danish women. The EUROMAP group. Eur J Clin Pharmacol 1999; 55: 139-44.